scholarly journals Smoking Cessation Treatment Programs Offered at Hospitals Providing Oncology Services

2018 ◽  
Vol 14 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Michael Shayne Gallaway ◽  
Eric Tai ◽  
Elizabeth A. Rohan
Keyword(s):  
Smoking Cessation ◽  
Tobacco Cessation ◽  
Treatment Programs ◽  
Treatment Cessation ◽  
Smoking Cessation Treatment ◽  
Treatment Services ◽  
Tobacco Treatment ◽  
Cessation Treatment ◽  
Quit Attempts ◽  
Discharged Patients

Background: Many people with cancer continue smoking despite evidence that it negatively effects cancer treatment, worsens chemotherapy toxicity, and increases risk for a second cancer.Aims: We examined tobacco treatment services offered to cancer patients at hospitals providing oncology services, including National Cancer Institute (NCI)-Designated Cancer Centers (NDCCs).Methods: We examined survey data of 6,400 U.S. hospitals from 2008 to 2015 to determine the manner in which tobacco treatment/cessation program services were provided among NDCCs and non-NDCC hospitals providing oncology services (HPOs).Results: From 2008 to 2015, 784 responses from NDCCs and 18,281 responses from HPOs were received. NDCCs (86%) reported significantly higher tobacco treatment/cessation programs owned by the hospital compared to HPOs (68%) (p < 0.001). Among NDCCs, there was a significant increasing trend of tobacco treatment/cessation programs reported owned by the hospital, the health system, or other contractual mechanism from 2008 to 2015 (p = 0.03).Conclusions: More than 80% of oncology providing hospitals report providing tobacco cessation programs, with higher percentages reported in NDCCs. As hospitals implement smoking cessation programs, partnerships between hospitals and cancer coalitions could help bring tobacco cessation activities to communities they both serve, and link discharged patients to these cessation resources so they can continue quit attempts that they initialised while hospitalised.

scholarly journals Identifying Barriers to Entering Smoking Cessation Treatment Among Socioeconomically Disadvantaged Smokers

2010 ◽  
Vol 5 (2) ◽  
pp. 164-171 ◽  
Author(s):  
Amy L. Copeland ◽  
Michael S. Businelle ◽  
Diana W. Stewart ◽  
Scott M. Patterson ◽  
Carla J. Rash ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Nicotine Dependence ◽  
Stage Of Change ◽  
Psychosocial Treatment ◽  
Treatment Programs ◽  
Smoking Rate ◽  
Socioeconomically Disadvantaged ◽  
Smoking Cessation Treatment ◽  
Cessation Treatment ◽  
Professional Assistance

AbstractBackground:Efficacious smoking cessation interventions exist, yet few smokers utilise available resources such as psychosocial treatment programs and pharmacotherapy. The goals of the present study were to (1) identify perceived barriers to entering smoking cessation treatment programs among socioeconomically disadvantaged smokers, who are presently underrepresented in smoking cessation interventions; (2) determine what variables are most important in predicting the barriers identified (i.e., age, gender, ethnicity, income, nicotine dependence level, smoking rate, years smoking, stage of change, presence of smoking-related illness and medical insurance status).Methods:Responses from socioeconomically disadvantaged smokers (N= 343) were collected in 2004–2005 and analysed to develop the Treatment Barriers Questionnaire, a 40-item measure of reasons for not entering smoking cessation programs. Study methods were approved by the Institutional Review Board of Louisiana State University; informed consent procedures were employed.Results:Principal components analysis yielded seven scales named for their theme: (1) Preparedness to Quit Smoking; (2) Work and Time Constraints; (3) Smokers Can or Should Quit on Own; (4) Opinions about Professional Assistance; (5) Mobility Limitations; (6) Insurance Limitations and (7) Misinformation about Professional Assistance. Gender, ethnicity, daily smoking rate, nicotine dependence and stage of change were significant predictors in regression analyses for scales 1,F(10, 201) = 7.83,p< .001,R2= .29, 2F(10, 201) = 2.30,p< .05,R2= .11, and 3,F(10, 201) = 3.58,p< .001,R2= .16. Conclusions: Results can inform efforts to facilitate entry and retention of smokers in cessation programs.

scholarly journals Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study

2018 ◽  
Vol 52 ◽  
pp. 22-28 ◽  
Author(s):  
João Mauricio Castaldelli-Maia ◽  
Aline Rodrigues Loreto ◽  
Bruna Beatriz Sales Guimarães-Pereira ◽  
Carlos Felipe Cavalcanti Carvalho ◽  
Felipe Gil ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Substance Use ◽  
Substance Use Disorders ◽  
Tobacco Use ◽  
Psychiatric Treatment ◽  
Nicotine Patch ◽  
Treatment Success ◽  
Smoking Cessation Treatment ◽  
Tobacco Treatment ◽  
Cessation Treatment

AbstractBackground:There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment.Methods:We compared treatment success between participants with (n = 277) and without (n = 419) MSUD among patients in a 6-week treatment provided by a Brazilian Psychosocial Care Center (CAPS) from 2007 to 2013. Sociodemographic, medical and tobacco use characteristics were assessed at baseline. Tobacco treatment consisted of 1) group cognitive behavior therapy, which included people with and without MSUD in the same groups, and 2) pharmacotherapy, which could include either nicotine patches, nicotine gum, bupropion or nortriptyline. For participants with MSUD, tobacco treatment was integrated into their ongoing mental health treatment. The main outcome was 30-day point prevalence abstinence, measured at last day of treatment.Results:Abstinence rates did not differ significantly between participants with and without MSUD (31.1% and 34.4%, respectively). Variables that were significantly associated with treatment success included years smoking, the Heaviness of Smoking Index, and use of nicotine patch or bupropion.Conclusions:The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population.

scholarly journals Integration of Tobacco Treatment Services into Cancer Care at Stanford

2020 ◽  
Vol 17 (6) ◽  
pp. 2101 ◽  
Author(s):  
Kathleen Gali ◽  
Brittany Pike ◽  
Matthew S. Kendra ◽  
Cindy Tran ◽  
Priya Fielding-Singh ◽  
...  
Keyword(s):  
Cancer Care ◽  
Tobacco Cessation ◽  
Cancer Center ◽  
Treatment Services ◽  
Tobacco Treatment ◽  
Cessation Treatment ◽  
Opt Out ◽  
Patient Reported ◽  
Delivery Options ◽  
One Year

As part of a National Cancer Institute Moonshot P30 Supplement, the Stanford Cancer Center piloted and integrated tobacco treatment into cancer care. This quality improvement (QI) project reports on the process from initial pilot to adoption within 14 clinics. The Head and Neck Oncology Clinic was engaged first in January 2019 as a pilot site given staff receptivity, elevated smoking prevalence, and a high tobacco screening rate (95%) yet low levels of tobacco cessation treatment referrals (<10%) and patient engagement (<1% of smokers treated). To improve referrals and engagement, system changes included an automated “opt-out” referral process and provision of tobacco cessation treatment as a covered benefit with flexible delivery options that included phone and telemedicine. Screening rates increased to 99%, referrals to 100%, 74% of patients were reached by counselors, and 33% of those reached engaged in treatment. Patient-reported abstinence from all tobacco products at 6-month follow-up is 20%. In July 2019, two additional oncology clinics were added. In December 2019, less than one year from initiating the QI pilot, with demonstrated feasibility, acceptability, and efficacy, the tobacco treatment services were integrated into 14 clinics at Stanford Cancer Center.

scholarly journals Smoking Cessation Treatment for Parents Who Dual Use E-Cigarettes and Traditional Cigarettes

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Emara Nabi-Burza ◽  
Jeremy E. Drehmer ◽  
Bethany Hipple Walters ◽  
M. C. Willemsen ◽  
Maurice P. A. Zeegers ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Usual Care ◽  
Replacement Therapy ◽  
Nicotine Replacement Therapy ◽  
Tobacco Cessation ◽  
Insurance Status ◽  
Dual Use ◽  
Smoking Cessation Treatment ◽  
The Past ◽  
Cessation Treatment

Introduction. An increasing number of parents use both e-cigarettes and cigarettes (dual users). Previous studies have shown that dual users may have higher rates of contemplating smoking cessation than parents who only smoke cigarettes. This study was aimed to assess the delivery of tobacco cessation treatment (prescription for nicotine replacement therapy and referral to the quitline) among parents who report being dual users vs. cigarette-only smokers. Methods. A secondary analysis of parent survey data collected between April and October 2017 at 10 pediatric primary care practices participating in a cluster-randomized controlled trial of the Clinical Effort Against Secondhand Smoke Exposure (CEASE) intervention was conducted. Parents were considered to be dual users of cigarettes and e-cigarettes if they reported smoking a cigarette, even a puff, in the past seven days and using an e-cigarette within the past 30 days. Parents were asked if they received a prescription for nicotine replacement therapy and referral to the quitline to help them quit from their child’s clinician. Multivariable logistic regression examined factors (dual use, insurance status, relationship to the child, race, and education status of the parent) associated with delivery of smoking cessation treatment (receiving prescriptions and/or enrollment in quitline) to smoking parents. Further, we compared the rates of tobacco cessation treatment delivery to dual users in the usual-care control practices vs. intervention practices. Results. Of 1007 smokers or recent quitters surveyed in the five intervention practices, 722 parents reported current use of cigarettes-only and 111 used e-cigarettes. Of these 111 parents, 82 (73.9%) reported smoking cigarettes. Parents were more likely to report receiving any treatment if they were dual users vs. cigarette-only smokers (OR 2.43, 95% CI 1.38, 4.29). Child’s insurance status, parents’ sex, education, and race were not associated with parental receipt of tobacco cessation treatment in the model. No dual users in the usual-care control practices reported receiving treatment. Discussion. Dual users who visited CEASE intervention practices were more likely to receive treatment than cigarette-only smokers when treatments were discussed. An increased uptake of tobacco cessation treatments among dual users reinforces the importance of discussing treatment options with this group, while also recognizing that cigarette-only smokers may require additional intervention to increase the acceptance rate of cessation assistance. This trial is registered with ClinicalTrials.gov, Identifier: NCT01882348.

Sign in / Sign up

Export Citation Format

Share Document